Market cap
$45.9m
End-of-day close multiplied by current shares on issue.
Effective tax rate jumped from 24.9% to 43.5%, deepening the NPAT decline to 67% while operating cash flow held essentially flat at $1.1m.
Revenue context before the current result.
Operating cash flow across covered periods.
Operating working-capital absorption or release by reporting period.
Statutory profit after tax across covered periods.
Market context
A close-dated read on what the market price implies next to the latest verified filing inputs. Unavailable metrics stay visible when the absence is useful context.
The latest close and share count context for the market price.
Market cap
$45.9m
End-of-day close multiplied by current shares on issue.
How the market price compares with recent earnings and cash-flow inputs.
P/E
16.39x
Recent market cap compared with trailing earnings.
EPS
0.28
Recent filing-derived earnings per share.
PEG
0.76x
P/E compared with recent earnings growth.
EV/EBITDA
7.67x
Enterprise value compared with recent EBITDA.
P/FCF
11.63x
Market cap compared with recent free cash flow.
P/B
8.33x
Market value compared with latest reported equity.
Yield and fund-style valuation where the company shape supports it.
Dividend yield
3.5%
Trailing dividends compared with the latest close.
Total return
Not available
Available once dividend and adjustment data are verified.
Key metrics
FY23 vs FY22
Revenue
$11.5m
+94.4% ↑ vs $5.9m
EBITDA
$1.6m
— vs —
Net profit after tax
$0.4m
-66.7% ↓ vs $1.2m
Net cash inflow from operating activities
$1.1m
+3.9% ↑ vs $1m
Full-year dividend per share
5.0c
-41.3% ↓ vs 8.6c
Profit before tax
$0.7m
-56.2% ↓ vs $1.6m
Cash and cash equivalents
$1.4m
+20.6% ↑ vs $1.1m
Total assets
$10m
+106.7% ↑ vs $4.9m
What changed
The effective tax rate climbed from 24.9% to 43.5%, which means NPAT fell roughly 10 percentage points further than PBT, so PBT is the cleaner read on operating performance. Group EBITDA was $1.6m (no comparable prior figure disclosed).
Operating cash flow was essentially unchanged at $1.1m (+3.9%) despite revenue doubling. The balance sheet expanded sharply: total assets more than doubled to $10.0m, gross borrowings of $2.3m now sit on the balance sheet against nil a year ago, and equity slipped 5.6% to $2.5m. Trade debtors more than tripled to $1.1m, lifting receivable days from 21.2 to 35.6. The release attributes $3.7m of revenue to recent acquisitions and $1.9m to organic growth (FY22 organic: $0.1m).
What matters
Capital raise adds balance-sheet context, with NZ$2m capital raised, but borrowings and gearing are the direct leverage evidence.
PBT declined 56.2% on a 94.4% revenue uplift, indicating the cost base expanded faster than the top line. This is the central tension in the result: management has built scale, but FY23 absorbed direct and indirect integration and consolidation costs in the first half that the second half did not fully recover. Until margin recovery is demonstrated in a clean period, the operating economics of the larger group remain unproven.
Tax distortion widened the headline decline. The effective tax rate moved from 24.9% to 43.5%, a roughly 18.6pp step-up. No driver is disclosed in the supplied material, so NPAT understates the underlying operating result and full reconciliation is outstanding. Investors should weight PBT over NPAT when judging FY23 performance.
Working capital absorbed cash that revenue would otherwise have produced. Operating cash flow rose just 3.9% while revenue rose 94.4%, because receivable days lengthened from 21.2 to 35.6 and operating working capital expanded by roughly $0.8m. This matters because it raises the cash cost of growth and, if it persists, will constrain dividend and debt-service capacity at the new larger scale.
Expectations
The half-year split is therefore the only available shape reference: 1H23 contained roughly 39.9% of full-year revenue and 44.6% of full-year EBITDA, but 74% of reported NPAT, so 2H reported NPAT was materially weaker than 1H ($0.1m vs $0.3m). Management points to underlying second-half improvement and a $150k annualised cost reduction; that framing is not visible in reported NPAT. The release does not provide enough to judge whether FY24 will inherit a recovered or still-compressed margin from the second half, which is the key open shape question.
Quality of result
On the positive side, capex remains very light at $0.1m (0.5% of revenue), so free cash flow pre-lease of roughly $1.0m closely tracks operating cash flow. Payout ratio versus pre-lease FCF is suppressed because the denominator basis is not suitable for numeric display. FCF/NPAT of 234.9% reflects the depressed NPAT denominator rather than unusually strong cash generation; OCF/EBITDA at 69.4% is more representative and suggests meaningful, but not exceptional, conversion.
Less durable signals dominate the read. Operating cash flow barely moved despite revenue doubling, because $0.8m of incremental working capital tied up the growth. The dividend at 122.4% of NPAT exceeds reported earnings cover, leaving FCF, not earnings, as the funding source for distributions. ROE fell from 43.5% to 17.2%, partly reflecting a larger asset base now carrying $2.3m of debt against $2.5m of equity. The combination of higher leverage, longer receivable days, and a tax line that has not been reconciled in the supplied disclosures means the FY23 print should not yet be treated as a clean baseline for forward earnings power.
Unresolved
This briefing cannot assess management's specific cost-reduction initiatives, segment-level margin trajectories, or FY24 trading momentum because the supplied material contains no forward financial guidance or post-period trading commentary.
Chat
Ask follow-up questions about Third Age Health Services's FY23 result.
Informational only. No buy, sell, hold, price-target, or personal financial advice.
Informational only. No buy, sell, hold, price-target, or personal financial advice.
Open to load segment breakdown.
Open to load analytical metrics.
Open to load key metrics.
Chair and CEO Update
FY23 / results releasePreliminary Results
FY23 / financial reportPresentation Highlights
FY23 / results presentationResults Announcement
FY23 / results announcementRelease of Annual Report 2022
FY22 / results announcementRelease of Annual Report 2022
FY22 / results releaseTAH Annual Report 2022
FY22 / financial reportInterim Report
HY23 / financial reportInterim Results Announcement
HY23 / results releaseTAH company filing
HY23 / results announcementRelated insights
Cross-company views selected from the metrics in this briefing.
Earnings quality and statutory distortions
PBT and NPAT growth diverged by 10.5pp, with a distortion flag in the result.
Cash conversion quality
This result converted 69.4% of EBITDA to operating cash flow.
Dividend coverage and payout pressure
Company-disclosed payout ratio is 75.0% on a NPAT basis, with NPAT payout at 122.4%.
Revenue growth context
Revenue growth was 94.4% for this reporting period.
Get the next Third Age Health Services briefing and related NZX reporting-season updates by email.